CCP
AVDL

Clough Capital Partners’s Avadel Pharmaceuticals AVDL Stock Holding History

Clough Capital Partners’s Portfolio AVDL Stock Details AVDL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-887,650
Closed -$12.7M – 178
2014
Q3 		$12.7M Buy
887,650
+2,100
+0.2% +$30.2K 0.48% 70
2014
Q2 		$13.3M Buy
+885,550
New +$10.7M 0.42% 94

Other funds holding AVDL

DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
CM
Castleark Management Chicago, Illinois $3.02B AUM 53.92% 1-Year Est. Return
BCM
Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return

Clough Capital Partners's AVDL Position: Q4 2014 in Review

Clough Capital Partners sold out of Avadel Pharmaceuticals (AVDL) in Q4 2014, closing a stake of 887,650 shares — an estimated $12.7M sold.

Clough Capital Partners first reported a position in AVDL in Q2 2014 and held it in 2 quarters. The position peaked at $13.3M in Q2 2014. 94 funds tracked by Wall St. Rank hold AVDL as of Q4 2014.

  • Clough Capital Partners reported no remaining Avadel Pharmaceuticals position as of Q4 2014 after selling out during the quarter.
  • Clough Capital Partners sold 887,650 Avadel Pharmaceuticals shares in Q4 2014, an estimated $12.7M.
  • Clough Capital Partners first reported a position in Avadel Pharmaceuticals in Q2 2014 and held it in 2 quarters.
  • Clough Capital Partners's Avadel Pharmaceuticals position peaked at $13.3M in Q2 2014.
  • 94 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q4 2014.

Based on Clough Capital Partners's 13F filing for Q4 2014, filed 17 Feb 2015.